XT
CADL icon

XTX Topco’s Candel Therapeutics CADL Stock Holding History

XTX Topco’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Sell
16,726
-27,037
-62% -$204K ﹤0.01% 3322
2026
Q1 		$214K Buy
43,763
+19,987
+84% +$109K ﹤0.01% 2793
2025
Q4 		$134K Buy
+23,776
New +$128K ﹤0.01% 2546
2025
Q3 		– Sell
-74,629
Closed -$378K – 2619
2025
Q2 		$378K Buy
+74,629
New +$384K 0.02% 1289

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

XTX Topco's CADL Position: Q2 2026 in Review

XTX Topco reduced its Candel Therapeutics (CADL) stake by 62% in Q2 2026, selling an estimated $204K and leaving 16,726 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #3322.

XTX Topco first reported a position in CADL in Q2 2025 and has held it in 4 quarters since. The position peaked at $378K in Q2 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • XTX Topco held 16,726 shares of Candel Therapeutics worth $172K as of Q2 2026.
  • XTX Topco sold 27,037 Candel Therapeutics shares in Q2 2026, an estimated $204K.
  • Candel Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3322 holding.
  • XTX Topco first reported a position in Candel Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • XTX Topco's Candel Therapeutics position peaked at $378K in Q2 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.